-
24 June 2024
Jubilant Radiopharma Announces Investment of $50 million (USD) to Expand Positron Emission Tomography (PET) Manufacturing Network
Jubilant Radiopharma’s Radiopharmacies division is excited to announce an investment of $50 million (USD) to expand its PET radiopharmaceutical manufacturing facilities by adding six (6) sites in strategic locations throughout the United States.
-
23 June 2023
Jubilant Radiopharma and Evergreen Theragnostics Announce Collaboration for the Sale and Distribution of Neuroendocrine Tumor Diagnostic OCTEVY™, (Kit for Preparation of Ga 68 DOTATOC Injection), pending FDA approval in 2H 2023
Jubilant Draximage Inc. (dba, Jubilant Radiopharma™), a Jubilant Pharma Company, through it's Radiopharmacy business division which maintains the second largest nuclear medicine pharmacy network in the US.
-
23 June 2023
Jubilant Radiopharma Introduces RUBY Mobile Solutions™
ubilant DraxImage Inc., dba Jubilant Radiopharma, a wholly-owned subsidiary of Jubilant Pharma Limited, is pleased to announce the clearance by the FDA to use its RUBY Rubidium Elution System™ and RUBY-FILL® (Rubidium Rb82 generator) in mobile settings.
-
September 22, 2021
Eckert & Ziegler’s GalliaPharm®, exclusively distributed by Jubilant Radiopharma, approved for use with NETSPOT in Canada
-
16 March 2021
Jubilant Radiopharma and Isotopia Molecular Imaging Enter into a Strategic Partnership to Further Advance the Field of Radiotherapeutics
Isotopia Molecular Imaging Limited (Isotopia) and Jubilant Radiopharma, a business division of Jubilant Pharma Limited, have entered into a strategic commercial partnership.
-
4 November 2020
Jubilant Radiopharma and SOFIE Biosciences Ink Strategic Partnership Deal to Further Advance the Field of Molecular Imaging & Therapeutics
-
31 August 2020
Eckert & Ziegler‘s GalliaPharm® to be distributed by Jubilant Radiopharma in Canada
-
10 August 2020
Jubilant Radiopharma and Navidea Biopharmaceuticals Sign Binding Memorandum of Understanding for Commercialization Partnership
-
March 18th, 2020
OUR COMPANY RESPONSE TO COVID-19
-
February 17th, 2020
JUBILANT RECEIVES FAVORABLE RULINGS FROM THE U.S. PATENT OFFICE INVALIDATING BRACCO RUBIDIUM-INFUSION-SYSTEM PATENTS
-
January 29th, 2020
Jubilant Radiopharma Receives Approval from Health Canada for Drax Exametazime® a Product Used to Diagnose Intra-Abdominal Infection and Inflammatory Bowel Disease
-
December 11th, 2019
FAVORABLE RULING FROM THE U.S. COURTS FOR RUBY-FILL®
-
October 25th, 2019
JUBILANT AWARDED PREMIER PURCHASING AGREEMENT
-
October 03rd, 2019
JUBILANT TO DISTRIBUTE STRONTIUM-89 CHLORIDE INJECTION USP IN THE U.S.
-
August 28th, 2019
QUALITY AND SAFETY IS AT THE CORE OF WHAT WE DO
-
August 12th, 2019
ITC FOUND THAT JUBILANT IMPORTATION AND SALE OF RUBY-FILL IN THE U.S. DOES NOT VIOLATE SECTION 337 OF THE TARIFF ACT OF 1930
-
July 23rd, 2019
IMPORTANT INFORMATION FOR CANADIAN NUCLEAR PHARMACISTS
-
July 19th, 2019
Important information for U.S. nuclear pharmacists and commercial radiopharmacies
-
June 17th, 2019
Introducing Jubilant Radiopharma
-
June 06th, 2019
RUBY Rubidium Elution System™ receives CE Mark Certificate
-
March 26th, 2019
New and Important Safety Information as Requested by the FDA
-
February 08th, 2019
Campaign to Support FDA Approved Products
-
September 28th, 2018
Family Health Campaign
-
August 13th, 2018
Jubilant initiates I-131 MIBG OPTIMUM Trial
-
April 06th, 2018
Important Customer Communication
-
December 30th, 2017
JDI receives FDA approval for new pulmonary indications for DRAXIMAGE® DTPA
-
November 06th, 2017
JDI to attend Miami Thyroid Oncology Symposium 2018
-
October 27th, 2017
Jubilant DraxImage receives FDA approval for 12-Hour shelf-life for DRAXIMAGE® MAA
-
September 28th, 2017
Jubilant DraxImage receives approval from Health Canada for the RUBY Elution System™ (RbES)
-
September 27th, 2017
ASNC 2013 in Chicago, IL
-
May 05th, 2017
Jubilant Pharma to acquire Triad Isotopes
-
January 19th, 2017
JDI participates to SNMMI Mid-Winter in Phoenix Arizona
-
April 09th, 2017
Jubilant DraxImage Appoints New Sales and Business Operations VP
-
October 21st, 2016
Michael Rossi: New President of Jubilant DraxImage.
-
October 03rd, 2016
JDI RECEIVES FDA APPROVAL for products
-
September 30th, 2016
No impact on I-131 supply from Chalk River shutdown
-
May 12th, 2016
JDI and CYC Licensing Agreement Update
-
May 03rd, 2016
Not all Iodine-131 is created equal
-
January 06th, 2016
Count On It DRAXIMAGE® MAA 350K Particles Campaign
-
December 03rd, 2015
Canada- Radioactive Iodine in Differentiated Thyroid Cancer; Patient Video
-
December 03rd, 2015
USA – Radioactive Iodine in Differentiated Thyroid Cancer; Patient Video
-
October 09th, 2015
Jubilant DraxImage launches HICON® in Colombia
-
September 14th, 2015
JDI-Cyclopharm Technegas Announcement
-
September 11th, 2015
September is Thyroid Cancer Awareness month
-
September 01st, 2015
ASNC 2015 – Washington, DC, Sept. 17-20 – booth 801
-
July 07th, 2015
New Endocrine Brand Portfolio Manager
-
May 19th, 2015
SNMMI 2015 – Baltimore, MD June 6 to 9 – Booth 853
-
May 08th, 2015
Canada: temporary shortage of Xenon-133
-
April 20th, 2015
Jubilant DraxImage Files Citizen Petition with the FDA
-
December 08th, 2014
New Lung Imaging Portfolio Manager
-
November 20th, 2014
RSNA 2014: Chicago, IL
-
October 20th, 2014
New Director – Manufacturing Operations
-
September 22nd, 2014
ASNC 2014, Boston, MA
-
August 19th, 2014
New Director – Commercial Operations for Latin America
-
May 15th, 2014
MAA Pricing: FAQ
-
May 12th, 2014
New USA Sales Director
-
April 18th, 2014
MAA Pricing: Investing in the Future of MAA & DTPA
-
March 01st, 2014
Action to ensure sustainability and continuity of supply of MAA/DTPA in USA
-
January 13th, 2014
Jubilant DraxImage Appoints New Marketing Director
-
November 08th, 2013
Japanese SNM 2013 in Fukuoka, Japan
-
September 06th, 2012
ASNC 2012 in Baltimore, MD